[Badly controlled severe persistent asthma: an additional new treatment].
Nomémie
Legendre
L
Hôpital Antonie Béclère, Paris.
Verpilleux
Marie-Pascale
MP
Ballouard
Karine
K
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000069444:Omalizumab; D012720:Severity of Illness Index
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab